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OBJECTIVE—To investigate the association of normal fasting plasma glucose (FPG) and the
risk for type 2 diabetes.
RESEARCH DESIGN AND METHODS—Data concerning 13,845 subjects, aged 40–69
years, who had their FPG measured at least three times between 1992 and 2008 were extracted
from a database. Three FPG groups were deﬁned (51–82, 83–90, and 91–99 mg/dL). A Cox
proportional hazards analysis was applied to estimate the risk of incident diabetes adjusted for
other risk factors.
RESULTS—During 108,061 person-years of follow-up (8,110 women and 5,735 men), 307
incidentcasesoftype2diabeteswerefound.Theﬁnalmodeldemonstratedahazardratioof2.03
(95% CI 1.18–3.50) for 91–99 mg/dL and 1.42 (0.42–4.74) for 83–90 mg/dL.
CONCLUSIONS—Our data suggest that FPG between 91 and 99 mg/dL is a strong inde-
pendent predictor of type 2 diabetes and should be used to identify people to be further in-
vestigated and aided with preventive measures.
Diabetes Care 34:1372–1374, 2011
T
he prevalence of type 2 diabetes is
increasing worldwide (1,2). Predic-
tion methods are a matter of discus-
sion (3–5). A recent study (6) showed an
alteration of normal linear trajectories for
fasting and postload plasma glucose con-
centrations and insulin sensitivity and se-
cretion 3–6 years before diagnosis. Other
studies (7,8) showed an increased risk of
developing type 2 diabetes among nor-
moglycemic subjects,p a r t i c u l a r l yi n
those with a fasting plasma glucose
(FPG)range of 91–99 mg/dL. Clear infor-
mation regarding Mediterranean popula-
tions is lacking. We investigated whether
the higher tertilesof within-normal-range
FPG concentrations in a northern Italian
population can help identify people at in-
creased risk.
RESEARCH DESIGN AND
METHODS—The Italian National
Health Service facilitates health controls;
on average, northern Italian individuals
haveoneannualblooddrawingwitheight
laboratory tests, including FPG. This in-
duced us to use retrospective outpatient
data of the Desio Hospital Laboratory to
model an experimental population.
Selection criteria were basal FPG
,100 mg/dL at inclusion; at least three
additional FPG measurements between
1992 and 2008; and total, HDL, and
LDLcholesterolandtriglyceridemeasure-
ments. Furthermore, they did not have
any requests for glycated hemoglobin, a
limit set to avoid inclusion of those with
type 1 and type 2 diabetes.
A total of 13,845 people, aged 40–69
years(9),wereconsidered.Thesesubjects
represented 17% of the corresponding
stratum (82,000), which is 41% (equiva-
lent to Milan province census data) of the
general population (200,000) referring to
our laboratory. Demographic and health
status information collected through a
questionnaire (from 1992 to 2008) was
available for a random (one of four con-
secutive) subset of 3,593 outpatients. We
diagnosed type 2 diabetes (study end
point) after two FPG concentrations
.125 mg/dL (10,11).
Blood samples, collected in lithium-
heparin tubes, were analyzed by the
enzymatic and colorimetric method
(GOD-PAP) within 2 h. Analytical vari-
ability was within 2% (12). Data were
stratiﬁed in groups according to three
FPG concentration ranges (51–82, 83–
90, and 91–99 mg/dL). Baseline charac-
teristics (mean age, follow-up time, and
lipids) across FPG groups were investi-
gated.
The Cochrane-Armitage trend test
was used to ﬁt the median of each bio-
marker in the FPG group to estimate two-
sided P values for trends of biomarkers
acrossgroupsofFPG.ACoxproportional
hazards analysis to estimate the hazard
ratios and 95% CIs for the development
of type 2 diabetes was applied; the values
for age, then for triglycerides and total,
HDL, and LDL cholesterol were subse-
quently added. The ﬁnal Cox model ap-
p l i e dt ot h es u b s e tg r o u pw i t hh e a l t h
status information was adjusted for sex,
age, triglycerides, total cholesterol, BMI,
hypertension, family history of type 2 di-
abetes,smoking,anddrinkinghabits.Sta-
tistical analyses were performed (SAS
version 8.3; SAS Institute, Inc., Cary,
NC).
RESULTS—Data from 8,110 women
and 5,735 men with mean (6SD) ages at
baseline of 53.8 6 8.18 and 54.1 6 8.24
years were observed for an average of 7.9
and 7.4 years (range 1–16 years), respec-
tively.TriglyceridesandLDLandtotalcho-
lesterol increased across FPG groups in
both sexes, whereas HDL cholesterol de-
creased only in women (Table 1).
The longitudinal assessment of
blood glucose levels and progression to
diabetes is reported in Supplementary
Table A1 and Supplementary Fig. A1.
During 108,061 person-years of
follow-up, there were 307 incident cases
oftype2diabetes.Incidencewas1.9%for
women and 2.7% for men. The incidence
of type 2 diabetes increased across FPG
groupsfrom0.75and0.58%inthe51–82
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Brambilla and Associatesmg/dL category to 3.37 and 4.08% in the
91–99 mg/dL category, respectively, for
women and men. In these groups, both
women and men developed type 2 diabe-
tes at a rate of 4.2 and 5.4 cases per 1,000
person-years, respectively.
Hazard ratios for type 2 diabetes
adjusted only for age increased across
groups of normal FPG, reaching 2.89
(95% CI 2.18–3.83) for women and
2.87 (2.03–4.04) for men in the highest
FPG group. Additional adjustment for
lipids did not signiﬁcantly change risk.
M e na n dw o m e ni nt h e9 1 –99 mg/dL cat-
egory showed the same hazard ratio
(Table 1). The ﬁnal model (not sex strat-
iﬁed), adjusted for recorded health status
information, showed a hazard ratio of
2.03 (1.18–3.50) for the 91–99 mg/dL
FPG category and 1.42 (0.42–4.74) for
the 86–90 mg/dL category (Table 1).
CONCLUSIONS—During the follow-
up of 13,845 apparently healthy Mediter-
ranean adults, we found an increased risk
of type 2 diabetes across FPG groups
within normal range (10,11), suggesting
that FPG between 91 and 99 mg/dL is a
strong independent predictor of diabetes.
This is in agreement with changes in glu-
cose concentrations, insulin sensitivity,
and secretion 3–6y e a r sb e f o r et h ed i a g -
nosis (6). The increased risk (2.03) in the
highest FPG group conﬁrms that of 2.33
observed by Nichols et al. (8). The results
indicate that elevated normal FPG may
help select people at higher risk for future
type 2 diabetes without the addition of
strong independent risk factors, such as
age, cholesterol, and triglycerides. Model
adjustment for hypertension, BMI, and
family history attenuates the hazard ratio
(from 2.8 to 2.03).
The FPG range of 91–99 mg/dL can
therefore be used to select those individ-
uals to be subjected to further investiga-
tion with biomarkers of b-cell function,
such as 1-h oral glucose tolerance test
(OGTT)(5,13).Infact,athreefolddecline
in insulin sensitivity was demonstrated
with increasing FPG levels from 70 to
125 mg/dL (14). The relationship be-
tween abnormal FPG and abnormal
OGTT to the development of type 2 di-
abetes still remains an open question be-
causesomeindividualsdevelopabnormal
FPGwithoutdevelopingabnormalOGTT
and vice versa (15).
Theincidenceofdiabetesinourstudy
(2.7%) is higher than that in Tirosh et al.
(7) (1.6%), perhaps because of the older
population (mean age 54.1 vs. 32 years),
yet is almost half of that (4.7%) described
by Nichols et al. (8), who used less strin-
gent criteria for diagnosis (only one FPG
measurement .125 mg/dL with respect
to our two) (10).
In conclusion, these results may help
physicians to better identify those individ-
uals who need further investigation and
preventive measures. They can therefore
support public health policy with an in-
expensive tool for improving care and
reducing costs of future treatment.
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